Citation
Thorp, John M., Jr.; Palacios, Santiago; Symons, James; Simon, James A.; & Barbour, Krista (2014). Improving Prospects for Treating Hypoactive Sexual Desire Disorder (HSDD): Development Status of Flibanserin. BJOG: An International Journal of Obstetrics & Gynaecology, 121(11), 1328-1331.Abstract
The condition of hypoactive sexual desire disorder (HSDD) has been included in the Diagnostic and Statistical Manual of Mental Disorders® (DSM) since DSM-III-R was first published in 1987. DSM-IV-TR (APA, 2000)[1] describes HSDD ‘as persistent or recurrent deficiency or absence of sexual fantasies and thoughts, and/or desire for, or receptivity to, sexual activity, which causes personal distress or interpersonal difficulties and is not caused by a medical condition or drug.’ Recently, the diagnostic criteria for HSDD have been under review as part of the process of producing the fifth edition of the DSM (seeURL
http://dx.doi.org/10.1111/1471-0528.12878Reference Type
Journal ArticleYear Published
2014Journal Title
BJOG: An International Journal of Obstetrics & GynaecologyAuthor(s)
Thorp, John M., Jr.Palacios, Santiago
Symons, James
Simon, James A.
Barbour, Krista